National Institutes of Health: all 11,571 studies

Page 12 of 116. Open to participants first (946), then studies with results posted, then the rest; newest registration first within each.

• Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic AgentsActive, not recruitingNCT04739800Phase 2Results posted
• Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent GlioblastomaActive, not recruitingNCT04729959Phase 2Results posted
• Mucosal Immunity Against Neisseria Gonorrhoeae After 4CMenB VaccinationCompletedNCT04722003Phase 2Results posted
• Genomics, Environmental Factors and Social Determinants of Cardiovascular Disease in African Americans Study (GENE-FORECAST): Sodium Intervention Trial (SIT)CompletedNCT04717336Not applicableResults posted
• Phase 1 Evaluation of (2R,6R)-HydroxynorketamineCompletedNCT04711005Phase 1Results posted
• Task-dependent Effects of TMS on the Neural Biomarkers of Episodic MemoryCompletedNCT04694131Not applicableResults posted
• Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent MalesCompletedNCT04692077Phase 2Results posted
• Anthrax AV7909 Liquid vs LyophilizedCompletedNCT04660201Phase 1Results posted
• Safety and Immunogenicity of an Epstein-Barr Virus (EBV) gp350-Ferritin Nanoparticle Vaccine in Healthy AdultsCompletedNCT04645147Phase 1Results posted
• Adaptive COVID-19 Treatment Trial 4 (ACTT-4)CompletedNCT04640168Phase 3Results posted
• Testing the Addition of an Anti-cancer Drug, Entinostat, to the Usual Chemotherapy and Immunotherapy Treatment (Atezolizumab, Carboplatin and Etoposide) for Previously Untreated Aggressive Lung Cancer That Has SpreadCompletedNCT04631029Phase 1Results posted
• Treatment of Cancer-Related Bone Pain by Using Bone-Targeted Radiation-Based Therapy (Sn-117m-DTPA) in Patients With Prostate Cancer That Has Spread to BonesTerminatedNCT04616547Phase 2Results posted
• Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid TumorsActive, not recruitingNCT04616534Phase 1Results posted
• Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell MalignanciesCompletedNCT04599634Phase 1Results posted
• COVID-19, Chronic Adaptation and Response to Exercise (COVID-CARE)Active, not recruitingNCT04595773Not applicableResults posted
• Acute Effects of Medium Chain Triglyceride (MCT) Nutritional Ketosis on Parkinson's Disease (PD) Symptoms and Biomarkers (MCT-PD)CompletedNCT04584346Phase 1Results posted
• ACTIV-5 / Big Effect Trial (BET-B) for the Treatment of COVID-19CompletedNCT04583969Phase 2Results posted
• ACTIV-5 / Big Effect Trial (BET-A) for the Treatment of COVID-19CompletedNCT04583956Phase 2Results posted
• PK and Safety of Remdesivir for Treatment of COVID-19 in Pregnant and Non-Pregnant Women in the USCompletedNCT04582266Results posted
• Fostamatinib for Hospitalized Adults With COVID-19CompletedNCT04579393Phase 2Results posted
• Dose, Safety, Tolerability and Immunogenicity of an Influenza H10 Stabilized Stem Ferritin Vaccine, VRC-FLUNPF0103-00-VP, in Healthy AdultsCompletedNCT04579250Phase 1Results posted
• Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck CancerActive, not recruitingNCT04576091Phase 1Results posted
• Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta "Trap"/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT)CompletedNCT04574583Phase 1/2Results posted
• HOPE Consortium Trial to Reduce Pain and Opioid Use in HemodialysisCompletedNCT04571619Phase 2Results posted
• Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC).TerminatedNCT04566133Phase 2Results posted
• Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual TreatmentActive, not recruitingNCT04557956Phase 1/2Results posted
• Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to TreatmentTerminatedNCT04541017Phase 1/2Results posted
• Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine TumorsTerminatedNCT04538378Phase 2Results posted
• Phase II Randomized Trial of Bethesda Protocol Compared to Cambridge Method for Detection of Early Stage Gastric Cancer in CDH1 Mutation CarriersCompletedNCT04535414Phase 2Results posted
• Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and IntestinesActive, not recruitingNCT04535401Phase 1Results posted
• Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate GlandCompletedNCT04530552Phase 2Results posted
• Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, LID/ΔM2-2/1030s, in RSV-Seronegative Infants and Children 6 to 24 Months of AgeCompletedNCT04520659Phase 1Results posted
• ACTIV-2: A Study for Outpatients With COVID-19CompletedNCT04518410Phase 2/3Results posted
• Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and PostpartumTerminatedNCT04518228Results posted
• Fixed Dose Flavonoid Isoquercetin on Thrombo-Inflammatory Biomarkers in Subjects With Stable Sickle Cell DiseaseCompletedNCT04514510Phase 2Results posted
• Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic CancerActive, not recruitingNCT04514497Phase 1Results posted
• Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIVActive, not recruitingNCT04514484Phase 1Results posted
• Grass Pollen Immunotherapy Plus Dupilumab for Tolerance InductionCompletedNCT04502966Phase 2Results posted
• A Phase II Study of Bintrafusp Alfa (M7824) in Checkpoint Inhibitor Naive and Refractory Subjects With Urothelial CarcinomaTerminatedNCT04501094Phase 2Results posted
• Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren's SyndromeActive, not recruitingNCT04496960Phase 1/2Results posted
• Adaptive COVID-19 Treatment Trial 3 (ACTT-3)CompletedNCT04492475Phase 3Results posted
• Phase II Trial of Combination Immunotherapy in Subjects With Advanced Small Bowel and Colorectal CancersCompletedNCT04491955Phase 2Results posted
• Red Cell Half Life Determination in Patients With and Without Sickle Cell DiseaseCompletedNCT04476277Early Phase 1Results posted
• E7 TCR T Cell Induction Immunotherapy for Stage IIB-IVA Cervical CancerTerminatedNCT04476251Early Phase 1Results posted
• Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction CancersActive, not recruitingNCT04460937Phase 1Results posted
• Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced ChondrosarcomaActive, not recruitingNCT04458922Phase 2Results posted
• Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal CancerTerminatedNCT04458909Phase 3Results posted
• Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell MalignanciesCompletedNCT04447027Phase 1Results posted
• Phase 1 Study of SAR440894 vs PlaceboCompletedNCT04441905Phase 1Results posted
• Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2)Active, not recruitingNCT04439357Phase 2Results posted
• Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A)Active, not recruitingNCT04439344Phase 2Results posted
• Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U)Active, not recruitingNCT04439331Phase 2Results posted
• Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1)Active, not recruitingNCT04439318Phase 2Results posted
• Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)Active, not recruitingNCT04439292Phase 2Results posted
• Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R)Active, not recruitingNCT04439279Phase 2Results posted
• Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F)Active, not recruitingNCT04439266Phase 2Results posted
• Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G)Active, not recruitingNCT04439253Phase 2Results posted
• Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W)CompletedNCT04439240Phase 2Results posted
• Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I)Active, not recruitingNCT04439227Phase 2Results posted
• Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subprotocol Z1D)CompletedNCT04439214Phase 2Results posted
• Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B)Active, not recruitingNCT04439201Phase 2Results posted
• Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of Expression (MATCH-Subprotocol P)Active, not recruitingNCT04439188Phase 2Results posted
• Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)Active, not recruitingNCT04439175Phase 2Results posted
• Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N)Active, not recruitingNCT04439149Phase 2Results posted
• Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B)Active, not recruitingNCT04439136Phase 2Results posted
• Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)Active, not recruitingNCT04439123Phase 2Results posted
• Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q)Active, not recruitingNCT04439110Phase 2Results posted
• Sylvatic Transmission of Zika, Dengue, and Chikungunya Viruses in Thailand and CambodiaCompletedNCT04434846Results posted
• HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated CancersCompletedNCT04432597Phase 1/2Results posted
• Ketone Ester Effects on Biomarkers of Brain Metabolism and Cognitive Performance in Cognitively Intact Adults 55 Years Old or OlderCompletedNCT04421014Not applicableResults posted
• A Phase 1 Trial to Evaluate CAP256V2LS in Healthy AdultsCompletedNCT04408963Phase 1Results posted
• Testing the Addition of a Radiation Sensitizing Drug, IPdR, to the Usual Chemotherapy Treatment (Capecitabine) During Radiation Therapy for Rectal CancerTerminatedNCT04406857Phase 1Results posted
• Adaptive COVID-19 Treatment Trial 2 (ACTT-2)CompletedNCT04401579Phase 3Results posted
• Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated GlioblastomaCompletedNCT04396860Phase 2/3Results posted
• COVID-19 and Anti-CD14 Treatment TrialTerminatedNCT04391309Phase 2Results posted
• COVID-19: Human Epidemiology and Response to SARS-CoV-2CompletedNCT04375761Results posted
• Tocilizumab for Patients With Cancer and COVID-19 DiseaseTerminatedNCT04370834Phase 2Results posted
• Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19TerminatedNCT04358068Phase 2Results posted
• Characterization of Skin Immunity to Aedes Aegypti Saliva in Dengue-endemic Participants in CambodiaCompletedNCT04350905Phase 1Results posted
• Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast CancerActive, not recruitingNCT04345913Phase 1/2Results posted
• Testing the Combination of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional ChondrosarcomaActive, not recruitingNCT04340843Phase 2Results posted
• Testing the Addition of Nivolumab to Chemotherapy in Treatment of Soft Tissue SarcomaActive, not recruitingNCT04339738Phase 2Results posted
• Evaluation of AMG 714 for VitiligoCompletedNCT04338581Phase 2Results posted
• Safety and Efficacy of CIS43LS Anti-malaria mAb in MaliCompletedNCT04329104Phase 2Results posted
• Immune Checkpoint Inhibitor M7824 and the Immunocytokine M9241 in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Advanced Pancreas CancerTerminatedNCT04327986Phase 1/2Results posted
• Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment TrialActive, not recruitingNCT04320888Phase 2Results posted
• Biased Opioid Agonists for Treatment of Opioid Withdrawal in OUDTerminatedNCT04316559Phase 2Results posted
• Clofazimine- and Rifapentine-Containing Treatment Shortening Regimens in Drug-Susceptible Tuberculosis: The CLO-FAST StudyTerminatedNCT04311502Phase 2Results posted
• Immersive Virtual Reality (VR) at the Time of Clinical Evaluation to Improve Psychological Distress and Anxiety in Primary Brain Tumor (PBT) PatientsCompletedNCT04301089Phase 2Results posted
• BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT)TerminatedNCT04296942Phase 1Results posted
• Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host DiseaseCompletedNCT04294641Phase 2Results posted
• STOP-T1D Low-Dose (ATG)TerminatedNCT04291703Phase 2Results posted
• Combination Immunotherapy in Subjects With Advanced HPV Associated MalignanciesCompletedNCT04287868Phase 1/2Results posted
• BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid LeukemiaActive, not recruitingNCT04284787Phase 2Results posted
• Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment TrialActive, not recruitingNCT04284774Phase 2Results posted
• Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19)CompletedNCT04283461Phase 1Results posted
• Adaptive COVID-19 Treatment Trial (ACTT)CompletedNCT04280705Phase 3Results posted
• A Multiple Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0361-0041CompletedNCT04279613Phase 1Results posted
• Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid LeukemiaCompletedNCT04277442Phase 1Results posted
• Drug-Drug Interactions Between Rifapentine and Dolutegravir in HIV/LTBI Co-Infected IndividualsTerminatedNCT04272242Phase 2Results posted

← National Institutes of Health overview and focus areas